Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

NCT ID: NCT00844675

Last Updated: 2012-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2012-03-31

Brief Summary

The purpose of this study is:

• To examine if oral administration of Pariet (proton pump inhibitor, 20mg tablets, twice daily for 5 days) before Endoscopic mucosal resection(EMR) exhibits preventive effects of ulcer bleeding compared with placebo group (preoperative administration of placebo)
• To evaluate the effects on the suppression of acid secretion of preoperative administration of an Proton pump inhibitor

Detailed Description

• Endoscopic mucosal resection (EMR) is less invasive than surgery and is known to be general treatment for early gastric cancer or gastric adenoma when patients' quality of life is taken into consideration. However, major complications such as bleeding and perforation remain to be problematic.1-5 The incidence of these complications is expected to rise as the size of lesions for which EMR is indicated has enlarged. Histamine 2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) have been used for the bleeding,1-3 but the bleeding rate following EMR has been reported to be still high as 1.4% to 24%.1,4 Green et al and Berstad et al cited in their research that intragastric PH should be sustained above 5.4 to prevent bleeding, and PPIs should be administered instead of H2RAs to keep PH above 5.4. Being studied are administration modalities to enhance the therapeutic efficacy of PPIs or H2RAs.1-3 Several studies have already demonstrated that high-dose PPI therapy, for which a PPI was administered twice daily, effectively blocks acid secretion by increasing intragastric pH to neutral.3 Our study team also suggested in a previous study that high-dose PPI therapy was adequate to maintain intragastric pH above 6.
• PPIs are known to induce the suppression of acid secretion because they destroy a proton pump, yet it takes 5 days to achieve their maximum effects.7,8 It's been suggested that the onset of PPIs is slow to prevent bleeding with administration of a PPI after EMR.4 Therefore, our investigators expect that 5-day administration of an oral PPI before EMR would increase intragastric pH to above 6 and would be at least equal to or superior to intravenous PPIs currently being used in terms of the suppression of acid secretion.
• This is a prospective, randomized, comparative study to substantiate that oral administration of rabeprazole (Pariet tablets) 20mg twice daily before and after EMR (PO RBP group) will show similar effects on the prevention of bleeding compared with the conventional treatment with iv administration of pantoprazole after EMR but no special medication given before EMR (Placebo group). In addition, we are going to measure intragastric pH among part of study subjects and then to evaluate if the effect of acid suppression in the PO RBP group is superior to that in the placebo group.

Conditions

Early Gastric Adenocarcinoma; Adenocarcinoma, Tubular

Keywords

endoscopic mucosal resection; Proton Pump Inhibitor; gastrointestinal hemorrhage; rabeprazole

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

rabeprazole

rabeprazole

Group Type: EXPERIMENTAL

rabeprazole

Intervention Type: DRUG

The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

placebo

placebo

Group Type: EXPERIMENTAL

placebo

Intervention Type: DRUG

The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

Interventions

rabeprazole

The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

Intervention Type: DRUG

placebo

The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

Intervention Type: DRUG

Other Intervention Names

Pariet(rabeprazole)

Eligibility Criteria

Inclusion Criteria

• Patients who have EMR planned as well as meet the criteria described below will be selected as study subjects
• Patients in whom EMR is indicated:

1. Gastric adenoma

2. Early gastric adenocarcinoma

• Moderately or well differentiated adenocarcinoma
• Gastric cancer limited to only mucosa on endoscopic ultrasonography
• No invasion of lymph nodes or metastases (diagnosed by CT)

3. EMR to be performed for other diagnostic purposes

• Women of child-bearing potential should avoid pregnancy
• Subjects who consented to a EMR procedure in writing

Exclusion Criteria

• Patients who meet the criteria described below should be excluded from study subjects:

1. Younger than 18 years old

2. Patients with a history of upper gastrointestinal surgery or vagotomy

3. Patients with serious adverse reactions secondary to cardiac, renal, hepatic, or hematologic diseases (e.g. creatinine> 2.5 mg/dl, total bilirubin >3.0 mg/dl)

4. Patients with diseases that may have a great impact on the clinical study

5. Patients to whom the stimulation of gastrointestinal movement poses risks as in gastrointestinal bleeding, mechanical ileus and perforation

6. Women who are pregnant or nursing

7. Patients who are being treated with adrenocorticoid steroids, nonsteroidal anti-inflammatory drugs including aspirin, or other ulcer inducers

8. Patients who are taking other antiulcer drugs (antacids, antihistamines, etc) that may affect the efficacy assessments of the study drug (but, except for patients not taking the drugs over 7 days)

9. Patients with severe psychiatric diseases

10. Patients who received other investigational drugs within 30 days prior to the start of this study or who are currently participating in other clinical study

11. Patients who did not consent to the clinical study

12. Patients who can not be examined

• Patients with bleeding tendency
• Patients with esophageal varices
• Patients with esophageal ulcer, stricture, or obstruction
• Patients who have pacemaker or implantable cardiac defibrillator in place

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Korea, Ltd., Korea

INDUSTRY

Sponsor Role: collaborator

The Catholic University of Korea

OTHER

Sponsor Role: lead

Responsible Party

Myung-gui Choi

MD, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

MyungKu Choi, MD

Role: PRINCIPAL_INVESTIGATOR

The Catholic University of Korea

Locations

Catholic University, Gangnam St. Mary's Hospital

Seoul, Ban-po Dong 505, South Korea

Countries

South Korea

Other Identifiers

RAB-KOR-9035

Identifier Type: -

Identifier Source: org_study_id